Does Florida Blue (Blue Cross Blue Shield of Florida) Cover Dupixent?

How Florida Blue Classifies Dupixent on Its Formulary

Florida Blue places Dupixent on its specialty tier (Tier 5 or Tier 6, depending on plan design), which carries the highest cost-sharing. Biologics like dupilumab are not listed on standard preferred or non-preferred brand tiers because their manufacturing cost, cold-chain shipping, and clinical monitoring requirements set them apart from small-molecule drugs. Florida Blue contracts with Prime Therapeutics as its pharmacy benefit manager for most commercial lines, routing specialty fills through a dedicated specialty pharmacy network [1].

This classification means members pay either a fixed copay (often $150 to $250 per fill) or coinsurance (typically 25% to 33% of the allowed amount after deductible). On a plan with 30% coinsurance and no copay card, a single month of Dupixent could cost a member more than $1,000 out of pocket. The distinction between copay and coinsurance models matters enormously for total annual spend, so checking the specific Summary of Benefits and Coverage document for your plan is the first practical step.

Florida Blue Medicare Advantage plans (branded BlueMedicare) also cover Dupixent, but cost-sharing follows the Part D or Part B medical benefit structure depending on whether the drug is self-administered or given in a clinical setting. For self-injected Dupixent pens used at home, coverage runs through the Part D pharmacy benefit, where members in the coverage gap (the so-called "donut hole") faced out-of-pocket costs up to 25% of the drug price before the Inflation Reduction Act's $2,000 annual cap took full effect in 2025 [2].

Prior Authorization: What Florida Blue Requires

Florida Blue requires prior authorization for every Dupixent prescription. The insurer's clinical policy follows closely the FDA-approved labeling and published guidelines from the American Academy of Dermatology and the Global Initiative for Asthma.

For atopic dermatitis, the standard criteria include: a confirmed diagnosis of moderate-to-severe AD (typically Investigator Global Assessment score of 3 or 4, or an Eczema Area and Severity Index score of 16 or higher); documented failure, intolerance, or contraindication to at least two conventional therapies such as topical corticosteroids, topical calcineurin inhibitors, or systemic immunosuppressants (cyclosporine, methotrexate, mycophenolate); and prescribing by or in consultation with a dermatologist or allergist [3].

For moderate-to-severe asthma, criteria typically require an eosinophilic phenotype (blood eosinophils of 150 cells per microliter or higher, or fractional exhaled nitric oxide of 25 ppb or higher) plus inadequate control on medium- to high-dose inhaled corticosteroids with a second controller [4]. The 2023 GINA report recommends dupilumab as an add-on biologic for patients with type 2 inflammation markers who remain uncontrolled on Step 4 or Step 5 therapy.

Authorization is initially granted for 6 to 12 months. Renewal requires documentation that the patient achieved measurable improvement, typically a 50% or greater reduction in EASI score for atopic dermatitis or a reduction in annualized exacerbation rate for asthma.

"Prior authorization exists to confirm medical necessity, not to deny care. When the clinical documentation is thorough, approval rates for biologics like dupilumab are high," noted Dr. Robert Sidbury, co-author of the AAD atopic dermatitis guidelines, in a 2023 interview [5].

Step Therapy Requirements and How to Satisfy Them

Step therapy is the most common barrier Florida Blue members encounter. The insurer requires a "fail-first" sequence before approving Dupixent. That sequence varies by indication.

For atopic dermatitis, a typical step therapy pathway looks like this. First, the patient must trial high-potency topical corticosteroids (such as clobetasol propionate 0.05%) for at least 4 weeks. Second, a topical calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%) or crisaborole must be tried or documented as inappropriate. Third, at least one systemic agent (cyclosporine, methotrexate, or azathioprine) must be tried or medically contraindicated [3].

If a patient has already completed these steps with a previous insurer or provider, Florida Blue accepts external documentation. Pharmacy records, prior authorization letters from another plan, or detailed chart notes showing dates of therapy, doses, and reasons for discontinuation can all fulfill the step therapy requirement without forcing the patient to restart failed treatments.

For asthma, the step therapy path requires documentation of adherence to inhaled corticosteroid/long-acting beta-agonist combinations (such as fluticasone/salmeterol or budesonide/formoterol) for at least 90 days, along with evidence of persistent uncontrolled symptoms or exacerbations during that period [4].

Florida statute 627.42392 gives patients and prescribers the right to request a step therapy exception. If the prescriber provides clinical justification that the required step would be ineffective, harmful, or has already been tried, Florida Blue must respond within 72 hours (or 24 hours for urgent requests).

What Dupixent Costs on a Florida Blue Plan

The out-of-pocket cost depends on the plan type, tier placement, and whether the member uses manufacturer support programs.

Dupixent's wholesale acquisition cost is approximately $3,546 for a 28-day supply of two 300 mg prefilled syringes. For a 200 mg every-two-weeks pediatric dose, the monthly cost is roughly $1,773 [6]. These are pre-insurance prices.

On a typical Florida Blue commercial PPO with a $3,000 deductible and 30% specialty coinsurance, the annual out-of-pocket trajectory would be: approximately $3 to 000 in deductible payments during the first month or two, followed by 30% coinsurance on subsequent fills until hitting the plan's out-of-pocket maximum (commonly $8,700 for individual coverage under ACA rules for 2026).

The Dupixent MyWay copay assistance program, run by manufacturer Regeneron/Sanofi, covers up to $13,000 per year in out-of-pocket costs for commercially insured patients [7]. Members with Florida Blue commercial plans (not Medicare or Medicaid) can enroll and reduce their per-fill cost to as little as $0. The program does not apply to government-funded insurance.

For Florida Blue Medicare Advantage members, the Part D $2,000 annual out-of-pocket cap introduced by the Inflation Reduction Act means that after reaching $2 to 000 in total Part D spending, the member pays nothing more for covered drugs for the rest of the calendar year [2]. This is a significant change from prior years when Medicare beneficiaries on specialty biologics could face $10,000 or more annually.

"The Inflation Reduction Act's out-of-pocket cap is the single most impactful policy change for Medicare beneficiaries on high-cost biologics in the last decade," said Dr. Stacie Dusetzina, professor of health policy at Vanderbilt University Medical Center, in a 2024 JAMA Health Forum analysis [8].

Filing an Appeal if Florida Blue Denies Dupixent

Denials happen. Common reasons include incomplete documentation, failure to meet step therapy requirements, or an off-label indication not covered by the plan's clinical policy.

When a denial occurs, Florida Blue issues a written explanation citing the specific clinical criteria the request did not meet. The member and prescriber then have 60 days to file a Level 1 internal appeal. The appeal is reviewed by a physician who was not involved in the original denial decision.

A strong appeal package includes: the denial letter with the specific reason highlighted; updated chart notes from the prescriber documenting disease severity scores (EASI, IGA, or asthma control test); a letter of medical necessity explaining why Dupixent is the appropriate next therapy; documentation of all prior treatments tried, including dates, durations, doses, and outcomes; and any relevant peer-reviewed literature supporting the use of dupilumab for the patient's condition.

If the Level 1 appeal is denied, members can request an external independent review through a state-certified Independent Review Organization. Florida's Department of Financial Services oversees this process, and the IRO's decision is binding on the insurer. For urgent situations (where delay could cause serious harm), an expedited external review can be completed within 72 hours [9].

In a 2022 KFF analysis of ACA marketplace plan denials, only 0.2% of denied claims were appealed internally, and roughly 40% of those appeals were overturned in the patient's favor [10]. The data suggest that many patients abandon the process prematurely.

FDA-Approved Indications That Florida Blue Covers

Florida Blue's clinical policy covers Dupixent for all six current FDA-approved indications. Understanding which indication applies to your condition determines the specific prior authorization criteria.

Atopic dermatitis in patients aged 6 months and older with moderate-to-severe disease not adequately controlled with topical therapies. The LIBERTY AD SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks achieved EASI-75 in 44% to 51% of patients versus 12% to 15% on placebo at week 16 [11].

Moderate-to-severe asthma in patients aged 6 and older with an eosinophilic phenotype or oral corticosteroid-dependent disease. The LIBERTY ASTHMA QUEST trial (N=1,902) showed a 47.7% reduction in annualized severe exacerbation rate with dupilumab versus placebo in patients with baseline eosinophils of 300 cells per microliter or higher [12].

Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is inadequately controlled. The LIBERTY NP SINUS-24 and SINUS-52 trials (combined N=724) showed significant improvement in nasal polyp score and nasal congestion severity [13].

Eosinophilic esophagitis (EoE) in patients aged 1 year and older weighing at least 15 kg. The LIBERTY EoE TREET trial (N=321) showed histologic remission (peak eosinophil count <6 per high-power field) in 60% of dupilumab-treated patients versus 5% on placebo at week 24 [14].

Prurigo nodularis in adults whose disease is not adequately controlled with topical therapy. The LIBERTY PN PRIME and PRIME2 trials (combined N=311) showed a 60% reduction in itch from baseline with dupilumab versus 37% with placebo at week 24 [15].

Chronic obstructive pulmonary disease (COPD) with type 2 inflammation. The BOREAS trial (N=939) demonstrated a 30% reduction in moderate-to-severe exacerbations with dupilumab versus placebo in COPD patients with blood eosinophils of 300 cells per microliter or higher [16]. The FDA approved this indication in September 2024.

Tips for Getting Dupixent Approved Faster on Florida Blue

Preparation before the prior authorization submission dramatically affects approval speed and success rates.

Have your prescriber document the diagnosis using standardized severity scores. For atopic dermatitis, request that your dermatologist calculate and record the EASI score and IGA at every visit. Quantified severity is harder to deny than narrative descriptions like "severe eczema."

Compile a complete medication history. Include every topical, oral, and injectable therapy tried, with specific drug names, doses, durations, and the clinical reason each was stopped. Pharmacy claims data from your Florida Blue member portal can supplement chart notes.

Request that your prescriber use Florida Blue's standardized prior authorization form rather than a freeform letter. Standardized forms map directly to the insurer's clinical criteria, reducing back-and-forth requests for additional information.

Ask your prescriber's office to submit the PA through the electronic prior authorization (ePA) system, which Florida Blue supports through CoverMyMeds and SureScripts. Electronic submissions are processed faster than fax-based requests, with many receiving a decision within 24 to 48 hours.

If you have a Florida Blue plan through your employer (a self-funded or ASO plan), note that the clinical criteria may differ from fully insured plans. Self-funded employers can customize their formulary and PA criteria, so the step therapy requirements described here may be more or less restrictive depending on the employer's benefit design. Contact the number on the back of your member ID card to confirm your plan's specific requirements.

Specialty Pharmacy and Delivery Logistics

Florida Blue requires Dupixent to be dispensed through its contracted specialty pharmacy network. For most commercial members, this means using Accredo (through the Prime Therapeutics/Express Scripts relationship) or another designated specialty pharmacy.

Specialty pharmacies provide cold-chain shipping (Dupixent must be stored at 2°C to 8°C until use), clinical counseling on self-injection technique, adherence monitoring, and coordination with the prescriber for refill authorizations. Members typically receive a 28-day supply shipped directly to their home in insulated packaging with cold packs.

First-fill coordination can take 7 to 14 days after prior authorization approval. The specialty pharmacy verifies benefits, applies any copay assistance, confirms the shipping address, and schedules a clinical intake call. Plan ahead so there is no gap between approval and the first injection.

Members can use the Dupixent prefilled pen (approved in 2022) or the original prefilled syringe. Both delivery devices contain the same formulation. The pen may be preferred by patients who are uncomfortable with visible needles, though the syringe allows the prescriber to specify exact dose adjustments for pediatric patients.